

Midterm Outcomes following Endovascular Repair of Complex Aortic Aneurysms in Patients with Connective Tissue Disorders

Presenter: Lucas Ribé MD,

Yuki Ikeno, Safa Savadi, Rana O Afifi, Akiko Tanaka, Lucas Ruitter, Gustavo Oderich.

April 25th 2024. Aortic Symposium. AATS- The American Association for Thoracic Surgery 104th Annual Meeting. The University of Texas Health Science Center at Houston.

Department of
Cardiothoracic &
Vascular Surgery

UTHealth
McGovern
Medical School
The University of Texas
Health Science Center at Houston

MEMORIAL
HERMANN
Heart & Vascular Institute
Texas Medical Center



Midterm Outcomes following Endovascular Repair of Complex Aortic Aneurysms in Patients with Connective Tissue Disorders



INTRODUCTION

- Connective tissue disorders (**CTDs**) primarily affecting the aorta and leading to severe cardiovascular manifestations include Marfan syndrome (MFS), Loeys-Dietz syndrome (LDS), vascular Ehlers-Danlos syndrome (vEDS), and Familial Thoracic Aortic Aneurysm and Dissection syndrome (FTAAD).
- There is very scarce literature documenting the use of **endovascular fenestrated or branched stent-grafts** for the management of CTDs, including both thoracoabdominal aneurysmal (TAAA) disease and dissection.



OBJECTIVE

The purpose of this study is to describe mid-term outcomes of patients with **connective tissue disorders (CTDs)** and thoraco-abdominal aortic aneurysms (TAAA) or dissections after complex endovascular procedures



METHODS

- From 2018 to 2013 we conducted a retrospective review of patients with connective tissue disorders (**CTDs**) who underwent endovascular repair with physician-sponsored investigational device exemption (**PS-IDE**) for treatment of TAAAs and complex aortic dissections, including Fenestrated-Branched endovascular aortic repair (**F-BEVAR**).
- Study participants were prospectively recruited from the Mayo Clinic Institution and Memorial Hermann Hospital at Texas Medical Center.
- We identified **330 patients** who underwent aortic reconstruction for aneurysms or dissection of the thoracoabdominal aorta.



METHODS

- **Follow-up** was conducted through outpatient physical examinations, stent-graft duplex ultrasounds, laboratory studies, and computed tomography angiograms (CTA) before discharge, as well as at 6- and 12-months post-intervention.
- Starting in 2020, cone-beam computed tomography (**CBCT**) was implemented.



RESULTS

- **Twelve patients** with CTDs were treated with a complex endovascular investigational device (ID) stent-graft for aortic dissection or aneurysm affecting the thoracoabdominal aorta.
- **Median** age was 72 years (interquartile range [IQR] 63-81).
- Eleven patients (92%) had previously undergone open aortic surgery.
- Eight patients (67%) had undergone prior endovascular aortic procedure.



RESULTS

Table 1. Patient Characteristics

Characteristic	No. (%)
	Connective Tissue Disorders (CTDs) (n= 12)
Age, (IQR), years	72 (63-81)
Sex	
Male	7 (58.3)
Female	5 (41.7)
Hypertension	11 (92)
Coronary artery disease	2 (17)
Peripheral artery disease	2 (17)
Previous cerebrovascular accident	2 (17)
Respiratory disease	2 (17)
Congestive heart failure	1 (8.3)
Kidney impairment	1 (8.3)
Previous open aortic surgery	11 (92)
Previous endovascular aortic repair	8 (66.6)

IQR: Interquartile range



RESULTS

Table 1. Patient Characteristics

Characteristic	No. (%)
	Connective Tissue Disorders (CTDs) (n= 12)
Age, (IQR), years	72 (63-81)
Sex	
Male	7 (58.3)
Female	5 (41.7)
Hypertension	11 (92)
Coronary artery disease	2 (17)
Peripheral artery disease	2 (17)
Previous cerebrovascular accident	2 (17)
Respiratory disease	2 (17)
Congestive heart failure	1 (8.3)
Kidney impairment	1 (8.3)
Previous open aortic surgery	11 (92)
Previous endovascular aortic repair	8 (66.6)

IQR: Interquartile range



RESULTS

Table 2. Endovascular procedure details and device type

Characteristic	Number (%)
Cerebrospinal fluid drain	3 (25)
Neuromonitoring	12 (100)
Device design	
F-BEVAR	5 (41.7)
Off-the-shelf T-Branch	5 (41.7)
PMEG	2 (16.7)
IBD	5 (41.7)
Femoral conduit	4 (33.3)
Unilateral	3 (75)
Bilateral	1 (25)
Ilio-femoral conduit	1 (8.3)
Unilateral	1 (100)
Bilateral	0 (0)
Percutaneous femoral	12 (100)
Unilateral	9 (75)
Bilateral	3 (25)
Sheath size, Fr	20 (18-22)
Upper extremity approach	6 (50)
Right	6 (100)
Left	0 (0)

Table 2. Endovascular procedure details and device type

Characteristic	Number (%)
Connective Tissue Disorders (CTDs) (n= 12)	
Procedure metrics	
Contrast volume, mL	158 (110- 306)
DAP, Gy-cm ²	703 (82- 676)
EBL, mL	340 (10- 1150)
Fluoroscopy time, minutes	79 (39- 217)
Target vessels per patient	4 (3-5)
Technical success	12 (100)
Total endovascular time, minutes	163 (128- 323)
Total operative time, minutes	220 (193- 327)
Total radiation dose (mGy)	1649 (385- 4756)



DISCUSSION

- Several series have concluded that **endovascular treatment for CTDs is feasible**, with high primary technical success and low 30-day mortality.
- However, significant gaps remain in data about later clinical and surgical complications and survival.

DISCUSSION

- We found that the rate of acute **kidney injury was very low (0%** in our study group), with only one patient (8.3%) presenting with spinal cord ischemia that resolved during the admission after CSF drain placement.
- **Primary technical success** has been reported ranging from 96-100%.
- Major complications in the first 30 days, including stroke, myocardial infarction, spinal cord injury, are low (0- 15%), with a low perioperative mortality rate.
- **Complications** may arise during the follow up: endoleaks, branch stenosis or occlusion, device migration, re-dissection, and retrograde dissection.

CONCLUSIONS

Patients with connective tissue disorders (CTDs) after endovascular interventions of complex TAAAs and dissections have an excellent early outcome.

However, in 40% of cases, minor and major complications could manifest in the early postoperative phase.

